Crestline Management LP reduced its holdings in Ionis Pharmaceuticals (NASDAQ:IONS) by 49.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 25,526 shares of the company’s stock after selling 25,431 shares during the quarter. Crestline Management LP’s holdings in Ionis Pharmaceuticals were worth $1,284,000 as of its most recent filing with the SEC.
Other large investors have also modified their holdings of the company. Steward Partners Investment Advisory LLC acquired a new stake in Ionis Pharmaceuticals during the third quarter valued at approximately $100,000. American International Group Inc. bought a new position in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $147,000. Parallel Advisors LLC raised its stake in shares of Ionis Pharmaceuticals by 60.3% in the third quarter. Parallel Advisors LLC now owns 3,323 shares of the company’s stock valued at $182,000 after acquiring an additional 1,250 shares during the last quarter. Icon Wealth Partners LLC bought a new position in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $182,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Ionis Pharmaceuticals by 9.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after acquiring an additional 311 shares during the last quarter. 90.72% of the stock is currently owned by institutional investors.
In other Ionis Pharmaceuticals news, Chairman Stanley T. Crooke sold 16,549 shares of the business’s stock in a transaction on Monday, January 15th. The stock was sold at an average price of $51.76, for a total transaction of $856,576.24. Following the sale, the chairman now directly owns 67,626 shares in the company, valued at $3,500,321.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Chairman Stanley T. Crooke sold 11,000 shares of the business’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $52.01, for a total value of $572,110.00. Following the sale, the chairman now owns 48,014 shares in the company, valued at $2,497,208.14. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 82,472 shares of company stock worth $4,296,151. Company insiders own 2.13% of the company’s stock.
A number of research analysts have recently issued reports on the stock. ValuEngine upgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, March 8th. TheStreet lowered shares of Ionis Pharmaceuticals from a “c” rating to a “d+” rating in a research note on Tuesday, February 27th. Zacks Investment Research downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 28th. BidaskClub upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 9th. Finally, BMO Capital Markets lifted their price objective on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $52.15.
Shares of IONS stock traded down $1.86 during midday trading on Friday, hitting $40.68. The company had a trading volume of 978,619 shares, compared to its average volume of 1,103,315. Ionis Pharmaceuticals has a 52-week low of $37.55 and a 52-week high of $65.51. The company has a market capitalization of $5,334.65, a P/E ratio of 508.50 and a beta of 2.49. The company has a current ratio of 5.20, a quick ratio of 5.15 and a debt-to-equity ratio of 1.45.
Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Tuesday, February 27th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.10. Ionis Pharmaceuticals had a negative return on equity of 1.94% and a negative net margin of 1.18%. The company had revenue of $172.00 million for the quarter, compared to the consensus estimate of $126.38 million. During the same period last year, the business posted $0.33 EPS. The company’s revenue was up 7.5% on a year-over-year basis. equities analysts predict that Ionis Pharmaceuticals will post -0.13 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/ionis-pharmaceuticals-inc-ions-stake-decreased-by-crestline-management-lp.html.
Ionis Pharmaceuticals Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.